Global High Content Screening Market Set to Surge, Projected to Reach USD 3 Billion by 2033 at a 5.8% of CAGR

High Content Screening
Global High Content Screening Market

The global high content screening market is poised for significant growth, with an overall valuation forecast to reach USD 1.6 billion in 2022. The demand for high content screening is expected to surge, driven by a projected compound annual growth rate (CAGR) of 5.8% in the coming years.

High content screening (HCS) is an advanced method used in drug discovery and biological research, enabling the simultaneous measurement of multiple cellular and biochemical parameters. The growing adoption of HCS technologies is attributed to their ability to provide detailed insights into complex biological processes, making them indispensable in various research and development applications.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426

High content screening is used in the process of discovering and creating novel medications. The use of high content screening is expected to accelerate over the projected years due to growing research into target identification and validation, as well as the search for novel medication candidates. In addition, throughout the course of the projection period, demand is anticipated to increase due to a persistent focus on producing high-quality and technologically sophisticated cell imaging systems.

However, the COVID 19 epidemic severely hindered research and development efforts. This is expected to have a negative impact on the market. Nonetheless, increasing investments by key manufacturers in the development of advanced cell imaging product is expected to boost the market in the coming years.

Key Takeaways

  • The CAGR for the global market over the preceding period was 5.1%.
  • Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.
  • With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.
  • Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.
  • The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.

The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis.” says an FMI analyst.

Competitive Landscape:

Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.

  • Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.
  • The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-426

Key Companies Profiled: 

  • Thermo Fisher Scientific Inc.
  • Becton Dickinson, and Company
  • GE Healthcare
  • Olympus Corporation
  • PerkinElmer Inc.
  • Sysmex Corporation
  • Merck KGaA
  • Danaher Corporation
  • Yokogawa Electric Corporation
  • BioTek Instruments Inc.

Key Segments Profiled in the High Content Screening Industry Survey:

Product Type:

  • Cell Imaging & Analysis
    • HCS Instruments
      • High-End HCS
      • Mid End HCS
      • Low-End HCS
    • Flow Cytometers
  • Consumables
    • Microplates
    • Reagents & Assay Kits
    • Other Consumables
  • Software
  • Services

Industry:

  • Pharmaceutical & Healthcare
  • Biotechnology
  • Educational Institutions
  • Independent CRO
  • Government Organizations
  • Others

Application:

  • Primary & Secondary Screening
  • Target Identification & Validation
  • Toxicity Studies
  • Compound Profiling
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Get Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/426

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *